drugset / Trial / NCT02707120

Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis

NCT02707120 ↗

Phase 4 Withdrawn Biotechnology Institute IMASD
RandomizedParallel-groupSingle-blindTreatment

Summary

Neurotrophic keratitis (NK) is a rare degenerative corneal disease caused by altered innervation of the trigeminal nerve that leads to rupture of the corneal epithelium, the regeneration deterioration and development of corneal ulceration, their fusion, and perforation The main characteristic in the NK is a decrease or absence of corneal sensitivity.

Timeline

Start
2018-01-04
Primary completion
2019-01
Completion
2020-01

Outcome

Outcome not reported

Stopped (Enrollment): “The study was suspended due to recruitment difficulties”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Artificial tears eye-drops Unknown — Topical
Subject PRGF-Endoret Protein / enzyme biologic — Topical